Artwork
iconShare
 
Manage episode 501368153 series 3369804
Content provided by Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).

Key Clinical Trials Discussed

1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL

2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL

3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)

4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL

5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL

6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL

7. Additional Studies Mentioned:

R-Pola-Glo Frail Study

DLBCL Classification

  continue reading

67 episodes